Topics

Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public

14:32 EST 15 Jan 2020 | BioPharmaDive

While Zolgensma's launch has gone well, the pharma still faces challenges in expanding the gene therapy's market and addressing criticism over its price.

Original Article: Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public

NEXT ARTICLE

More From BioPortfolio on "Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public"

Quick Search

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...